2017
DOI: 10.21037/jgo.2017.01.03
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background: Patients with liver metastatic colorectal cancer (mCRC) often benefit from receiving 90 Y-microsphere radioembolization (RE) administered via the hepatic arteries. Prior to delivery of liverdirected radiation, standard laboratory tests may assist in improving outcome by identifying correctable preradiation abnormalities. Methods: A database containing retrospective review of consecutively treated patients of mCRC from July 2002 to December 2011 at 11 US institutions was used. Data collected include… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
9
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 12 publications
(11 citation statements)
references
References 34 publications
(31 reference statements)
2
9
0
Order By: Relevance
“…Screening of such Y-RE treatment. It has also been previously suggested that correction of anemia before 90 Y-RE treatment (for instance, by blood transfusion or subcutaneous erythropoietic) may improve survival outcomes (13). Consistent with a previous report, we found no significant difference in survival outcomes between elderly patients ≥70 years and those younger ( Table 2).…”
Section: Discussionsupporting
confidence: 92%
See 1 more Smart Citation
“…Screening of such Y-RE treatment. It has also been previously suggested that correction of anemia before 90 Y-RE treatment (for instance, by blood transfusion or subcutaneous erythropoietic) may improve survival outcomes (13). Consistent with a previous report, we found no significant difference in survival outcomes between elderly patients ≥70 years and those younger ( Table 2).…”
Section: Discussionsupporting
confidence: 92%
“…• Low baseline hemoglobin levels and laboratory values indicative of liver dysfunction (levels of albumin, alkaline phosphatase, aspartate aminotransferase, alanine transaminase, bilirubin, and creatine) were significantly associated with decreased median survival times across all lines of prior chemotherapy (13). …”
Section: Updated Survival Analysis Of the Entire More Cohortmentioning
confidence: 97%
“…Patients who are clinically unsuitable for SIRT in the salvage setting include those with extensive uncontrolled extrahepatic disease or abnormal liver function tests (54).…”
Section: Rationale and Recommendationsmentioning
confidence: 99%
“…90 Y-resin microspheres are approved by the Food and Drug Administration (FDA) for the treatment of mCRC that has spread to the liver, and a number of safety and efficacy studies have been published involving patients with mCRC with liver metastases. Radioembolization using 90 Y-resin microspheres to treat liver-only or liver-dominant mCRC has been successful in this refractory setting (68), and combining regorafenib and 90 Y-RE is an attractive option as an anti-tumor and maintenance treatment for the refractory mCRC population.…”
Section: Introductionmentioning
confidence: 99%